ABOUT ELITE
Overview
Our Facility
Management & Key Employees
Our Board
Careers
PRODUCTS
PIPELINE
Generic
Branded
TECHNOLOGY
Technology Overview
How It Works
One Bead System
Two Bead System
INVESTOR RELATIONS
Press Releases
Events & Presentations
SEC Filings
Shareholder Meeting
Governance Documents
Investor Contacts
Email Alerts
HOME
|
CAREERS
|
CONTACT
|
NEWS
|
Skip to content
About Elite
Overview
Management & Key Employees
Our Board
Careers
Products
Pipeline
Generic
Branded
Technology
Technology Overview
How It Works
One Bead System
Two Bead System
Investor Relations
Press Releases
Events & Presentations
SEC Filings
Shareholder Meeting
Governance Documents
Investor Contacts
Email Alerts
Investor Relations
Press Releases
Events &Presentations
SEC Filings
ShareholderMeeting
GovernanceDocuments
Investor Contacts
Email Alerts
Press Releases
Select:
Show All
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
Archived
Jun 10, 2013
Elite Laboratories Files Citizen Petition With The Fda On Brompheniramine Maleate And Pseudoephedrine Hcl Extended Release
May 21, 2013
Elite Pharmaceuticals Announces Change In Executive Leadership
Apr 23, 2013
Elite Pharmaceuticals Awarded Second U.S. Patent For Abuse Resistant Drug Formulation
Apr 22, 2013
Elite Pharmaceuticals, Inc. Secures $10 Million Funding Commitment From Lincoln Park Capital Fund, Llc
Apr 11, 2013
Elite Pharmaceuticals, Inc. Announces First Shipment Of Generic Phentermine Capsules
Feb 13, 2013
Elite Pharmaceuticals, Inc. Announces Fiscal Year 2013 Third Quarter Investor Conference Call on Tuesday, February 19, 2013
Feb 06, 2013
Elite Pharmaceuticals Announces Fda Approval Of Supplemental Application For Naltrexone
Jan 28, 2013
Elite Pharmaceuticals, Inc. Announces First Shipments From Expanded 15,000 Square Foot Facility
Dec 13, 2012
ELITE PHARMACEUTICALS, INC. ANNOUNCES AGREEMENT FOR SUPPLY OF PHENTERMINE ACTIVE INGREDIENT
Dec 10, 2012
ELITE PHARMACEUTICALS ANNOUNCES AMENDMENT TO BRIDGE LOAN FACILITY
12
13
14
15
16
17
18
19
20
21
22
<<
<
>
>>
Back to top
Privacy